- Home
- KRRO vs ABOS Comparison
KRRO vs ABOS Comparison
Compare KRRO & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRRO | ABOS |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.1M | 114.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KRRO | ABOS |
|---|---|---|
| Price | $11.63 | $2.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $54.60 | $7.50 |
| AVG Volume (30 Days) | 294.9K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $145.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.20 | $0.86 |
| 52 Week High | $55.89 | $3.05 |
Technical Indicators
Market Signals| Indicator | KRRO | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 55.89 |
| Support Level | $10.81 | $2.33 |
| Resistance Level | $12.46 | $2.65 |
| Average True Range (ATR) | 1.11 | 0.25 |
| MACD | -0.12 | -0.01 |
| Stochastic Oscillator | 16.69 | 31.55 |
Price Performance
Historical ComparisonAbout KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.